{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-011130","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2022-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.203410+00:00","generated_at":"2026-06-27T11:57:32.348727+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merck Q4 2021 revenue $13.5B (+24%), Non-GAAP EPS $1.80; FY2022 guidance issued","bullets":["Q4 2021 sales $13.5B (+24% YoY); GAAP EPS $1.51, Non-GAAP EPS $1.80 (vs $0.98).","Full-year 2021 sales $48.7B (+17%); GAAP EPS $4.86, Non-GAAP EPS $6.02.","KEYTRUDA FY sales $17.2B (+20%); GARDASIL/GARDASIL 9 sales $5.7B (+44%).","Molnupiravir contributed $952M in Q4; Animal Health sales $5.6B (+18%).","FY2022 guidance: sales $56.1-$57.6B, GAAP EPS $5.76-$5.91, Non-GAAP EPS $7.12-$7.27."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-011130","json":"https://secwatch.observer/filing/0001104659-22-011130.json","markdown":"https://secwatch.observer/filing/0001104659-22-011130.md","text":"https://secwatch.observer/filing/0001104659-22-011130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465922011130/0001104659-22-011130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465922011130/tm222755d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T11:57:32.348727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}